The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Looking to the future of CNS lymphoma management
In this video, Andrés Ferreri, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, looks to the future of central nervous system (CNS) lymphoma treatment, highlighting the need for prospective trials to investigate novel immunotherapies in this indication. Dr Ferreri notes that the blood-brain barrier remains a significant limitation, but researchers are working to overcome this challenge. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We hope that in the near future we will be able to conduct prospective trials addressing the efficacy and the safety of new forms of immunotherapy, in particular some cell therapies like new CAR T-cell therapies and the use of ADCs and bispecifics. Probably the combination of these agents could help to improve disease control and then to offer a consolidation to a higher proportion of patients...
We hope that in the near future we will be able to conduct prospective trials addressing the efficacy and the safety of new forms of immunotherapy, in particular some cell therapies like new CAR T-cell therapies and the use of ADCs and bispecifics. Probably the combination of these agents could help to improve disease control and then to offer a consolidation to a higher proportion of patients.
Obviously, the blood-brain barrier remains a limitation for the use of some of these, in particular, monoclonal antibodies and other large molecules that we use to treat other B-cell lymphomas, but there are some groups of researchers that are working on overcoming this main limitation to improve the outcome in these poor prognosis patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
